A Study to Assess PV-10 Chemoablation of Cancer of the Liver

• ClinicalTrials.gov Identifier: NCT00986661
• Recruitment Status: Active, not recruiting
• First Posted: September 30, 2009
• Last Update Posted: November 2, 2022
• Sponsor: Provectus Biopharmaceuticals, Inc.
• Information provided by (Responsible Party): Provectus Pharmaceuticals ( Provectus Biopharmaceuticals, Inc. )

Study Description

Brief Summary:

This open-label study will evaluate the safety, tolerability, pharmacokinetics and effect on tumor growth following a single intralesional injection of PV-10 in subjects with either (a) hepatocellular carcinoma (HCC) that is not amenable to resection, transplant or other potentially curative therapy or (b) cancer metastatic to the liver.

Condition or disease	Intervention/treatment	Phase
Cancer Metastatic to the Liver; Hepatocellular Carcinoma; Metastatic Melanoma; Metastatic Ocular Melanoma; Metastatic Uveal Melanoma; Metastatic Lung Cancer; Metastatic Colon Cancer; Metastatic Colorectal Cancer; Metastatic Breast Cancer; Metastatic Pancreatic Cancer	Drug: PV-10 (10% rose bengal disodium)	Phase 1

Detailed Description:

Subject will be enrolled in one of four planned cohorts (Main Study Group, Expansion Cohort 1, Expansion Cohort 2 or Expansion Cohort 3).

Main Study Group. Three initial subjects with either HCC or cancer metastatic to the liver will receive 0.25 mL PV-10 per cc lesion volume (Lv) to a single lesion (up to a maximum dose of 7.5 mL PV-10). If none of the initial three subjects experiences a new and persistent CTCAE Grade 3 or greater non-hematological or any Grade 4 hematological toxicity over a 28-day follow-up interval, an additional three subjects will be enrolled and similarly treated with PV-10 administered at 0.50 mL per cc Lv (up to a maximum dose of 15 mL PV-10) provided no new and persistent Grade 3 or greater non-hematological or any Grade 4 hematological toxicity occurs.

Expansion Cohort 1 (EC1: PV-10 plus/minus Checkpoint Inhibition). Following demonstration of safety and tolerability in the Main Study Group, up to 48 additional subjects with cancers metastatic to the liver or with HCC will be enrolled into Expansion Cohort 1 (EC1). Subjects will be treated with PV-10 administered at 0.50 mL per cc Lv (up to a maximum dose of 15 mL PV-10). Subjects may receive injection of up to two lesions in any PV-10 treatment cycle. Enrollment will continue provided no new and persistent Grade 3 or greater non-hematological (excluding fatigue) or any Grade 4 hematological toxicity occurs.

Expansion Cohort 2 (EC2: PV-10 plus Checkpoint Inhibition). Following demonstration of safety and tolerability in the Main Study Group, up to 12 additional subjects with HCC on a background of standard care checkpoint inhibition therapy (i.e., anti-PD-1 therapy) will be enrolled into Expansion Cohort 2 (EC2). Subjects will be treated with PV-10 administered at 0.50 mL per cc Lv (up to a maximum dose of 15 mL PV-10). Subjects may receive injection of up to two lesions in any PV-10 treatment cycle. Enrollment will continue provided no new and persistent Grade 3 or greater non-hematological (excluding fatigue) or any Grade 4 hematological toxicity occurs.

Expansion Cohort 3 (EC3: PV-10 plus Checkpoint Inhibition). Following demonstration of safety and tolerability in the Main Study Group, up to 12 additional subjects with hepatic metastases of uveal melanoma (mUM) on a background of standard care checkpoint inhibition therapy (i.e., anti-CTLA-4, anti-PD-1 or combination anti-CTLA-4 and anti-PD-1 therapy) will be enrolled into Expansion Cohort 3 (EC3). Subjects will be treated with PV-10 administered at 0.50 mL per cc Lv (up to a maximum dose of 15 mL PV-10). Subjects may receive injection of up to two lesions in any PV-10 treatment cycle. Enrollment will continue provided no new and persistent Grade 3 or greater non-hematological (excluding fatigue) or any Grade 4 hematological toxicity occurs.

Concomitant therapy with immune checkpoint inhibition is allowed in Expansion Cohort 1 and required in Expansion Cohort 2 and Expansion Cohort 3. This concomitant therapy must commence at least 7 days prior to initial PV-10 administration.

Subjects in each Expansion Cohort one or more additional injectable tumor ≥ 1 cm in diameter will be eligible for treatment of one or more additional injectable tumor 28 days to 6 months after prior PV-10 administration provided that any prior treatments with PV-10 were well tolerated. This may be repeated until all injectable tumors ≥ 1 cm in diameter have received PV-10.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 78 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant
• Study Start Date: October 2009
• Estimated Primary Completion Date: December 2022
• Estimated Study Completion Date: February 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: PV-10 Injection (Intralesional); Subjects in each of three cohorts will receive a single dose of PV-10 to one Target Lesion.	Drug: PV-10 (10% rose bengal disodium); Subjects will receive a single injection of PV-10 to a single Target Lesion (0.25 mL PV-10 per cc lesion volume, Lv, or 0.50 mL PV-10 per cc Lv).

Outcome Measures

Primary Outcome Measures :

1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of hepatic administration of PV-10 [ Time Frame: 28 days ]
   Systemic and locoregional Adverse Events (AEs) will be graded by CTCAE v4.0 and coded according to MedDRA; AE data for all subjects in the 1st cohort will be assessed prior to dose escalation. Final assessment use AE data for all subjects

Secondary Outcome Measures :

1. PV-10 distribution [ Time Frame: 3 months ]
   Lesion distribution and retention of PV-10 following injection assessed by CT
2. Objective response rate (ORR) [ Time Frame: 3 months ]
   Objective response rate (ORR) of Target and measurable Bystander Lesions (if present) by 2D EASL and/or RECIST criteria
3. Changes in markers of hepatic function [ Time Frame: 3 months ]
   Changes in markers of hepatic function, including ALP, ALT, AST, total bilirubin
4. Pharmacokinetics of PV-10 [ Time Frame: 28 days ]
   Pharmacokinetics of PV-10 in the bloodstream following intralesional injection; samples will be obtained immediately prior to PV-10 injection and at 2, 4, 8, 24 and 72 hours, and 7, 14 and 28 days to assess uptake and excretion of PV-10
5. Overall survival [ Time Frame: Assessed every 3 months for up to 100 months ]
   Overall survival will be assessed for the intent-to-treat population

Other Outcome Measures:

1. Exploratory Correlative Endpoints [ Time Frame: 28 days ]
   Serial correlative samples may be collected from subjects in each Expansion Cohort to evaluate potential changes in subjects' immunologic activity in response to PV-10 treatment; samples will be analyzed at one or more Sponsor-designated central laboratory

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age 18 years or older, males and females.
• Histologically or cytologically confirmed, or clinically diagnosed based on currently accepted standards, cancer metastatic to the liver or HCC that is not amenable at the time of enrollment to resection, transplant or other potentially curative therapy.
• At least one Target Lesion determined to be amenable to percutaneous injection by the treating physician.
• Target Lesion(s) must have measurable disease, defined as a unidimensionally measurable lesion ≥ 1.0 cm in longest diameter by helical CT; the maximum diameter of Target Lesion(s) shall be ≤ 4.9 cm.
• Performance status of Karnofsky scale 60%-100% or ECOG performance scale 0-2.
• Life expectancy ≥ 12 weeks.
• Hematopoietic Function: WBC ≥ 2,500/mm3; ANC ≥ 1000/mm3; Hemoglobin ≥ 8 g/dL; Platelet count ≥ 50,000/mm3; Coagulation: INR ≤ 1.3.
• AST and ALT < 5 times ULN; ALP < 5 times ULN; Bilirubin ≤ 1.5 times ULN; Creatinine ≤ 1.5 times ULN and eGFR ≥ 50.
• Thyroid Function: Total T3 or free T3, total T4 or free T4 and THS ≤ CTCAE Grade 2 abnormality.
• Renal Function: Adequate renal function in the opinion of the Investigator with no clinically significant renal impairment or uncontrolled renal disease.
• Cardiovascular Function: Adequate cardiovascular function in the opinion of the Investigator with no clinically significant uncontrolled cardiovascular disease.
• Respiratory Function: Adequate respiratory function in the opinion of the Investigator with no clinically significant uncontrolled respiratory disease.
• Immunological Function: Adequate immune system function in the opinion of the Investigator with no known immunodeficiency disease.
• Informed Consent: Signed by the subject prior to screening.

Exclusion Criteria:

• Target Lesion(s) must not be contiguous with, encompass or infiltrate major blood vessels.
• Primary HCC amenable to resection, transplant or other potentially curative therapy.
• Surgery: Subjects who have received hepatic surgery, ablation or chemoembolization within 4 weeks of PV-10 administration.
• Radiation Therapy: Hepatic radiation within 4 weeks of PV-10 administration.
• Chemotherapy: Chemotherapy within 4 weeks of PV-10 administration (6 weeks for nitrosoureas or mitomycin C).
• Investigational Agents: Investigational agents within 4 weeks (or 5 half-lives) of PV-10 administration.
• Phototoxic or Photosensitizing Agents: Concomitant agents posing a clinically significant risk of photosensitivity reaction within 5 half-lives of PV-10 administration.
• Concurrent or Intercurrent Illness: Impaired wound healing due to diabetes; Significant concurrent or intercurrent illness, psychiatric disorders or alcohol or chemical dependence that would compromise Subject safety or compliance or interfere with interpretation of the study; Uncontrolled thyroid disease or cystic fibrosis; Presence of clinically significant acute or unstable cardiovascular, cerebrovascular (stroke), renal, gastrointestinal, pulmonary, immunological (with the exception of the presence of hepatitis B virus (HBV), viral hepatitis, or cirrhosis), endocrine, or central nervous system disorders; Current encephalopathy or current treatment for encephalopathy; Variceal bleeding requiring hospitalization or transfusion within 4 months of screening; History of human immunodeficiency virus or acquired immune deficiency syndrome; The clinical presence of ascites.
• Pregnancy: Female subjects who are pregnant, lactating or have positive serum β HCG pregnancy test taken within 7 days of PV-10 administration; Fertile subjects who are not using effective contraception (e.g., oral contraceptives, intrauterine devices, double barrier methods such as condoms and diaphragms, abstinence or equivalent measures).

Contacts and Locations

Locations

United States, California

Sharp Memorial Hospital

San Diego, California, United States, 92123

United States, Florida

Florida Hospital Tampa

Tampa, Florida, United States, 33613

United States, Pennsylvania

St Luke's University Health Network

Bethlehem, Pennsylvania, United States, 18015

United States, Tennessee

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

United States, Texas

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Sponsors and Collaborators

Provectus Biopharmaceuticals, Inc.

Investigators

• Study Director: Eric Wachter, PhD; Provectus Biopharmaceuticals, Inc.

More Information

• Responsible Party: Provectus Biopharmaceuticals, Inc.
• ClinicalTrials.gov Identifier: NCT00986661
• Other Study ID Numbers: PV-10-LC-01
• First Posted: September 30, 2009
• Last Update Posted: November 2, 2022
• Last Verified: October 2022

Keywords provided by Provectus Pharmaceuticals ( Provectus Biopharmaceuticals, Inc. ):

melanoma; uveal; ocular; mUM; mOM; OM; UM; pancreatic; colon; colorectal; lung; metastatic; carcinoid; neuroendocrine; liver; hepatic

Additional relevant MeSH terms:

Carcinoma; Melanoma; Carcinoma, Hepatocellular; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Skin Diseases; Adenocarcinoma; Liver Neoplasms; Liver Diseases